Summary:
- This study compared the effectiveness and safety of tofacitinib, a Janus kinase (JAK) inhibitor, versus calcineurin inhibitors in patients with interstitial lung disease (ILD) secondary to anti-melanoma differentiation-associated gene 5 (anti-MDA5) positive dermatomyositis.
- The study found that tofacitinib was associated with improved lung function and reduced risk of acute exacerbations compared to calcineurin inhibitors in this patient population.
- The results suggest that tofacitinib may be a more effective treatment option for managing ILD in anti-MDA5 positive dermatomyositis patients, though larger studies are needed to confirm these findings.